Alebund Pharmaceuticals (Jiangsu) Limited (Alebund Pharma) disclosed on 02 November 2026 that it bought back 58,300 H-shares on the Hong Kong Stock Exchange under its existing share repurchase mandate approved on 14 August 2026. The transaction, executed entirely on-market, represents 0.02% of the company’s issued shares (excluding treasury shares) as of 30 September 2026.
The repurchase was completed at prices ranging from HKD 16.57 to HKD 17.19 per share, yielding a volume-weighted average price of HKD 17.08. Total cash outlay amounted to HKD 0.996 million.
Post-transaction, Alebund Pharma’s issued share capital (excluding treasury shares) stands at 235.58 million shares, down from 235.64 million. All repurchased shares have been retained as treasury shares, lifting the treasury stock balance to 58,300 shares, while the company’s total issued share count remains unchanged at 235.64 million.
The purchase utilised 0.25% of the 23.56 million-share buyback authority granted in August, leaving 99.75% of the mandate untapped. In line with Hong Kong Stock Exchange requirements, the company is subject to a moratorium on issuing new shares or selling treasury shares until 02 December 2026.
Joint Company Secretary Mr. Chen Nanyou confirmed that the buyback complied with the Main Board Listing Rules and that no material changes have occurred to the previously published explanatory statement.
Comments